Buy & Sell Ascendis Pharma A/S (ASND) – Ascendis Pharma A/S Price Today
Aura AI Summary
Key Stats
- $14.74BMarket Cap
- HealthSector
- -11.83%3M Drawdown
- $15.12BEnterprise Value
- -Dividend Yield
- 50 daysTypical Hold Time
Ascendis Pharma A/S (ASND) is currently valued at a market capitalization of $14.74B, with an enterprise value of $15.12B. Over the past 52 weeks, Ascendis Pharma A/S has traded between a low of $151.25 and a high of $249.84, highlighting its annual price range. Over the past three months, Ascendis Pharma A/S has recorded a drawdown of -11.83%, reflecting recent price volatility. On average, investors hold Ascendis Pharma A/S for approximately 50 days, indicating typical investor behavior on the platform.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Most Recent News
BTS Group to present Q1 2026 interim report on May 21 with live Q&A session
BTS Group AB, a global consultancy specializing in strategy execution and people development, will present its Q1 2026 interim report on May 21 at 08:00 am CEST. The presentation, led by CEO Jessica Skon and moderated by analyst Johan Sundén, will be...
Chinese crude oil imports drop 20% in April, easing pressure on global oil prices.
China's crude oil imports fell 20% month-over-month in April to 8.2 million barrels per day, the lowest in two years and nearly 30% below pre-war levels. This significant drop, equivalent to Japan's total daily oil consumption, may help ease the upwa...
Anaveon presents positive ANV600 cancer drug data at ASCO 2026, seeks partners for oncology assets.
Anaveon announced positive Phase 1 clinical data for its cancer drug ANV600, showing safety and early tumor shrinkage benefits, at the ASCO 2026 meeting. ANV600 targets PD-1 to boost immune response against tumors, including in resistant cases, and i...
